SCHEMBL13959039

SCHEMBL13959039

CC(C)(C)NCc1ccc(C(=O)N2CCN(c3ccc(Cl)cc3)CC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.63
▸ HSP90AA1 P07900 1/20 0.60
▸ SMN1; SMN2 Q16637 6/20 0.59
▸ HTT P42858 4/20 0.59
▸ NPSR1 Q6W5P4 2/20 0.59
▸ ALDH1A1 P00352 5/20 0.59
▸ MAPT P10636 6/20 0.58
▸ AKR1C3 P42330 1/20 0.57
▸ MEN1 O00255 3/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ TSHR P16473 3/20 0.53
▸ MAPK1 P28482 2/20 0.53
▸ USP2 O75604 2/20 0.53
▸ POLB P06746 3/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ MITF O75030 1/20 0.53
▸ TP53 P04637 1/20 0.51
▸ NAMPT P43490 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13959027 0.88 HSP90AA1 (0.60) LMNAHSP90AA1SMN1; SMN2HTTALDH1A1
SCHEMBL13959023 0.88 RAB9A (0.61) LMNASMN1; SMN2HTTNPSR1ALDH1A1
SCHEMBL13959031 0.87 SMN1; SMN2 (0.55) LMNASMN1; SMN2HTTALDH1A1MAPT
SCHEMBL13972823 0.84 LMNA (0.64) LMNAHSP90AA1SMN1; SMN2HTTNPSR1
SCHEMBL24158074 0.82 LMNA (0.85) LMNAHSP90AA1SMN1; SMN2HTTALDH1A1
SCHEMBL13959049 0.81 ACHE (0.55) LMNASMN1; SMN2HTTNPSR1ALDH1A1
SCHEMBL13959037 0.80 SLC6A7 (0.67) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL10901774 0.79 LMNA (0.70) LMNAHSP90AA1SMN1; SMN2HTTNPSR1
SCHEMBL1711137 0.78 LMNA (0.64) LMNAHSP90AA1SMN1; SMN2HTTNPSR1
SCHEMBL13959029 0.77 MEN1 (0.70) LMNASMN1; SMN2HTTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090011977-A1 Novel Lipopeptides as Antibacterial Agents HILL JASON 2009-01-08 — — US disclosed
US-20080287347-A1 Novel Lipopeptides as Antibacterial Agents CUBIST PHARMACEUTICALS, INC. 2008-11-20 — — US disclosed
US-20080287347-A1 Novel Lipopeptides as Antibacterial Agents CUBIST PHARMACEUTICALS, INC. 2008-11-20 — — US disclosed
US-7408025-B2 Lipopeptides as antibacterial agents CUBIST PHARMACEUTICALS, INC. (US) 2008-08-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287347-A1 Novel Lipopeptides as Antibacterial Agents CLPTM1, NGLY1, VIP LMNA 1625/4885HSP90AA1 1602/4885SMN1; SMN2 4753/4885
US-20090011977-A1 Novel Lipopeptides as Antibacterial Agents CLPTM1, NGLY1, VIP LMNA 1625/4885HSP90AA1 1602/4885SMN1; SMN2 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback